PT3:01 Feasibility of extrarenal systemic lupus erythematosus disease modification in GLADEL 2.0, a Latin American cohort

Objectives The concept of disease modification (DM) was recently introduced to improve the long-term care of patients (pts) with SLE. To claim DM ultimately requires delayed/prevented progression of organ damage beyond 5 years. The concept of DM is valuable for assessing ‘whether an intervention is on track for achieving DM at the 5-year mark,’ based on interim evaluations during the first 5 years. Latin American pts with SLE are prone to poorer outcomes, which are associated with disease severity and social determinants of health (SDH). We evaluated the prevalence of extrarenal DM in Latin American pts with SLE and examined SDH and treatment based on achievement of extrarenal DM.Methods GLADEL 2.0 included adults who fulfilled 1982/1997 ACR and/or 2012 SLICC classification criteria for SLE (43 centers; 10 Latin-American countries). Composite definition of DM for extrarenal SLE: (i) significant reduction in SLEDAI (>3 points), (ii) no severe flares, and (iii)